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A mega-analysis of expression 
quantitative trait loci (eQTL) 
provides insight into the regulatory 
architecture of gene expression 
variation in liver
Tobias Strunz1,2, Felix Grassmann2, Javier Gayán1, Satu Nahkuri1, Debora Souza-Costa1, 
Cyrille Maugeais1, Sascha Fauser1, Everson Nogoceke1 & Bernhard H. F. Weber  2
Genome-wide association studies (GWAS) have identified numerous genetic variants in the human 
genome associated with diseases and traits. Nevertheless, for most loci the causative variant is 
still unknown. Expression quantitative trait loci (eQTL) in disease relevant tissues is an excellent 
approach to correlate genetic association with gene expression. While liver is the primary site of gene 
transcription for two pathways relevant to age-related macular degeneration (AMD), namely the 
complement system and cholesterol metabolism, we explored the contribution of AMD associated 
variants to modulate liver gene expression. We extracted publicly available data and computed the 
largest eQTL data set for liver tissue to date. Genotypes and expression data from all studies underwent 
rigorous quality control. Subsequently, Matrix eQTL was used to identify significant local eQTL. In 
total, liver samples from 588 individuals revealed 202,489 significant eQTL variants affecting 1,959 
genes (Q-Value < 0.001). In addition, a further 101 independent eQTL signals were identified in 93 of 
the 1,959 eQTL genes. Importantly, our results independently reinforce the notion that high density 
lipoprotein metabolism plays a role in AMD pathogenesis. Taken together, our study generated a first 
comprehensive map reflecting the genetic regulatory landscape of gene expression in liver.
Large genome-wide association studies (GWAS) have led to the identification of risk-associated variants with 
genome-wide significance for a multitude of diseases1. The very first successful GWAS identified an associa-
tion between the complement factor H (CFH) locus on chromosome 1q31.3 and late stage age-related macular 
degeneration (AMD), the most common cause of blindness in industrialized countries2. The International AMD 
Genomics Consortium (IAMDGC) recently reported the most up-to-date list of genetic associations with 52 
independent variants in 34 loci involved in AMD risk greatly extending our understanding of the genetic archi-
tecture of this blinding disease3. As one result, non-synonymous variants in five genomic loci point towards an 
involvement of the complement cascade as part of the innate immunity system4–6, implicating genes such as com-
plement component 2 (C2), 3 (C3), 4 (C4), 9 (C9) as well as complement factor H (CFH), I (CFI), and B (CFB) in 
AMD pathology.
In addition, four AMD-associated loci harbour genes involved in high density lipoprotein (HDL) metabo-
lism7–9. So far, the functional variants in the potential HDL-metabolism genes are not unambiguously identified, 
mainly due to extensive linkage disequilibrium between the strongest associated variants and other correlated 
variants regularly offering multiple plausible genes as disease-associated candidates. Although statistical methods 
can help to further reduce the number of candidate variants10, most of the signals associated with AMD are local-
ized within non-coding regions of the genome3. These regions, however, may harbour sequences directly linked 
to gene expression such as 5′-prime untranslated regions or intronic sequences. On the other side, non-coding 
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regions are often intergenic but nevertheless can have an effect such as recruiting transcription factors, which in 
turn can influence expression of nearby genes11. In general, such loci potentially harbour regulatory sequences in 
cis or trans to the gene regulated by the associated genetic variant.
Correlating the allele count at a variant locus and the expression of nearby genes in a given tissue can bridge 
the gap between the observed genetic association and understanding the mechanisms responsible for disease 
risk by defining an expression quantitative trait locus (eQTL)12. In recent years, thousands of eQTL were iden-
tified in multiple tissues by genome- and transcriptome-wide approaches13. Disease-associated genetic markers 
that represent a significant eQTL for a nearby gene can thus easily be identified. For AMD, so far only a sin-
gle eQTL (rs79037040) affecting the expression of the tumor necrosis factor receptor superfamily, member 10a 
(TNFRSF10A) in white blood cells was reported to be associated with disease risk14. The lack of additional eQTL 
involved in AMD pathology can possibly be attributed to the observation that many eQTL studies are greatly 
underpowered15,16. In addition, although around 50% of known eQTL are common to several tissues13, many 
eQTL are likely to be specific for a given tissue or cell type.
The primary site of disease in AMD is the retinal tissue complex consisting of the retinal pigment epithelium 
(RPE), Bruch’s membrane and the choriocapillaris. The function of the liver is fundamentally different from the 
retina; thus the liver likely will react differently to environmental influences than retinal tissue. Furthermore, 
eQTL in liver might behave differently in retinal cells. However, it is challenging to sample a large number of 
human retinae and, as a consequence, no eQTL data from one of these cell types have been reported to date. Thus, 
we aimed at performing eQTL analysis in a surrogate tissue which expresses several genes of interest in loci asso-
ciated with AMD, with the assumption that a polymorphism could have similar effects on gene expression in the 
surrogate tissue as in the retina. We selected liver as surrogate tissue since it is the main tissue for expression of 
genes of the complement system and of HDL metabolism. Moreover, gene products (e.g. proteins) of complement 
and of HDL metabolism expressed by the liver are frequently secreted into circulation where they exert various 
biological activities, and which could consequently influence AMD through its systemic effect in the choriocap-
illaris. With this rational we anticipated that investigating eQTL of these genes in liver could reveal important 
mechanistic insights into the association of these loci with AMD.
Several previous studies have published eQTL from liver tissue using different genotyping and expression 
profiling platforms17–20. Raw or curated data files of these studies are publicly available. In the present study, 
we have jointly analysed the data from the four independent liver eQTL resources by state-of-the-art methods, 
subsequent to rigorous quality control. In addition, the results were compared to published GWAS data for AMD 
risk variants. We show that a common, AMD associated deletion of the complement factor H related 1 and 3 
genes (CFHR1/3) results in a markedly reduced expression of both genes in the liver. Furthermore, we show 
that two AMD risk variants are significant eQTL in liver affecting the expression of two genes involved in HDL 
metabolism.
Results
Data preparation. The main objective of this study was to identify significant cis-eQTL in liver tissue as part 
of our long-term goal to understand the functional consequences of genetic variants associated with complex 
diseases such as AMD. To this end, individual datasets publically available were merged although each one used 
distinct platforms to call genotypes and to measure gene expression (Table 1). Consequently, stringent quality 
control measures were applied to compile a data set of high quality genotypes and gene expression values compa-
rable across studies. Altogether, the study comprised 6,256,941 imputed variants and expression values of 24,123 
genes in 588 samples of European descent.
eQTL Analysis. First, we performed eQTL calculations for each of the four studies individually13,17–19. Local 
eQTL were calculated by including all variants on the same chromosome that are located within 1,000,000 base 
pairs (1 Mbp) up- or downstream of the transcription start site or polyadenylation site of a gene locus, respec-
tively. Next, mixed effects models were used to perform a meta-analysis by including the effect sizes and standard 
errors obtained from each study separately. In order to account for multiple testing, we controlled the false discov-
ery rate (FDR) to be smaller than 0.00121. At this threshold, 101,148 eQTL variants and 1,313 genes differentially 
regulated by the eQTL were identified (Table 1).
As meta-analysing data can result in a loss of statistical power22–24, we additionally performed a mega-analysis 
by directly estimating eQTL in the entire dataset comprising all four studies. The mega-analysis yielded 202,489 
statistically significant eQTL variants affecting the expression of 1,959 genes while controlling the FDR to be less 
than 0.001 (Fig. 1, Table 1 and Supplementary Table S1). Compared to the results from the meta-analysis, the 
mega-analysis provided a two fold increase in the number of eQTL variants and a 1.5 fold increase in the number 
of differentially regulated genes. Of note, however, both mega- and meta-analysis discovered more significant 
results than any of the four individual studies alone (Table 1). Only 38.5 to 60.9% of the significant single study 
eQTL genes could be replicated in the meta-analysis. The GTEx study had the lowest replication rate, possibly 
due to its relatively small sample size (N = 83). The overlap of single study results and the mega-analysis is on 
average 19% higher (53.5 to 80.15%) than the overlap observed in the meta-analysis. As the mega-analysis repro-
duced 95.96% of the meta-analysis eQTL and detected many signals beyond, we decided to rely on the data of the 
mega-analysis for further calculations although this may represent a slight overestimation of eQTL derived from 
the available data set.
We next aimed to identify independent eQTL variants (independent hits) within a significant eQTL. 
Consequently, the eQTL analysis was repeated for each significant eQTL gene after additionally adjusting the 
linear regression model for the most significant variant identified for the eQTL gene. The procedure was reiter-
ated until no additional significant variants were identified. In this analysis, a variant was regarded a significant 
independent eQTL for a given gene if the P-value associated with the regression slope was lower than 1 × 10−6. 
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With this approach, we detected an additional 101 independent eQTL variants in 93 out of 1,959 liver eQTL genes 
(Fig. 1, Supplementary Tables S2 and S3). Of note, our analysis could not replicate the AMD associated eQTL 
rs797037040 previously shown to influence the expression of TNFRSF10A in blood14. This is owed to the fact that 
neither this variant nor any variant in linkage disequilibrium (R > 0.4) to rs797037040 could be reliably imputed 
into the dataset.
Characterization of eQTL-variants. We further localized all independent eQTL hits with regard to the 
transcription start site (TSS) of the affected gene (Fig. 2). We observed that the most significant eQTL variants 
were close to a respective TSS. Overall, 1,599 out of 2,060 (1,959 + 101) independent eQTL variants were within 
100,000 base pairs of a nearest TSS, well in agreement with other studies16,25–27.
We then evaluated the RegulomeDB28 scores of eQTL variants (Fig. 3A and Supplementary Table S4). As expected, 
eQTL variants (N = 183,872) were enriched in RegulomeDB classes one to four (P-values < 6.82 × 10−09), which rep-
resent variants with likely regulatory properties while categories 5 and higher show minimal to no functional rel-
evance. In addition, eQTL variants with the smallest P-values and additional secondary signals (independent hits, 
N = 2,040) revealed an even stronger enrichment in classes one to four compared to controls and compared to all 
eQTL variants (P-values from 1.72 × 10−04 to 8.27 × 10−11).
To further characterise each eQTL signal for its most severe functional consequence relative to a known gene 
structure, we applied Ensembl VEP29,30 (Fig. 3B, Supplementary Table S5). Control variants were predominantly 
located upstream (49.22%) and downstream (49.09%) of known gene structures. Another 1.63% of the con-
trol variants were found in introns of genes. Less than 0.1% of the control variants were assigned to functional 
Study Schadt et al.18 Schroeder et al.19 Innocenti et al.17 GTEx Start/Mida Meta-analysis Mega-analysis
Sample size before/after QC 178/178 149/149 208/178 97/83 588 588
Origin of liver tissue
Post-mortem tissue 
and resections from 
donor livers
Normal tissue resected 
during surgery for 
liver cancer
Post mortem tissue 
and resections 
from donor livers
Post mortem tissue — —
Transcriptome profiling platform Agilent Custom 44k Illumina Human WG-6v2.0 Agilent 4 × 44 k
RNA-seq (Illumina 
HiSeq2000) — —
Probes/genes before QC 40,638 48,701 45,015 56,318 — —
Genes after QC 24,123 24,123 24,123 24,123 24,123 24,123
Genotyping platform Affymetrix 500k; Illumina 650 Y
Illumina 
HumanHap300 Illumina 610 Quad
Illumina Omni 
5 M/2.5 Ma — —
Variants before QC 449,699 318,237 620,901 2,526,494/2,378,075a — —
Variants after QC 383,719 296,718 545,886 2,389,798/2,119,410a — —
Variants merged before imputationb 861,575 861,575 861,575 861,575 861,575 861,575
Variants after imputation and QC 6,256,941 6,256,941 6,256,941 6,256,941 6,256,941 6,256,941
eQTL variants (Q-Value < 1 × 10−3) 29,546 71,423 52,565 19,802 101,148 202,489
eQTL variants (Q-Value < 1 × 10−3, unique) 27,689 69,292 49,594 16,953 95,257 183,872
eQTL genes (Q-Value < 1 × 10−3, unique) 363 913 670 387 1,313 1,959
Overlapping eQTL genes with meta-analysis 
(Q-Value < 1 × 10−3) 215 (59.23%) 491 (53.78%) 408 (60.9%) 149 (38.5%) 1,313 (100%) 1,260 (64.32%)
Overlapping eQTL genes with mega-
analysis (Q-Value < 1 × 10−3) 288 (79.34%) 688 (75.36%) 537 (80.15%) 207 (53.49%) 1,260 (95.96%) 1,959 (100%)
Independent signals (P-Value < 1 × 10−6) — — — — — 2,060
Table 1. Study and sample summary QC = quality control; aOmni 2.5 M for the first data release (GTEx start) 
and Omni 5 M for the mid-point release (GTEx mid). bAfter quality control the genotype files of the four studies 
were merged into a single file and variants, which did not overlap in-between datasets, were assigned missing. 
We only kept variants which were genotyped in at least 100 samples.
Figure 1. Manhattan plot of the eQTL mega-analysis in liver. A mega-analysis was conducted including 588 
samples from four independent studies measuring eQTL variants in liver tissue. The Manhattan plot shows the 
−log10 Q-Values of the most significant variant for each of the 24,123 analysed autosomal genes. Additionally, 
101 independent secondary signals were identified and are highlighted in red. The blue line depicts the 
threshold for significance at 1 × 10−3.
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categories such as missense or untranslated transcript region (UTR). Interestingly, the proportion of intronic 
variants was significantly larger in both, the mega-analysis variants (19.72%, P < 1.00 × 10−150) and the inde-
pendent hit variants (29.17%, P < 1.00 × 10−150) (Fig. 3B, Supplementary Table S5). Additionally, other predicted 
categories like UTR or coding region variants occurred more often (P-values < 1.72 × 10−07).
Taken together, our findings indicate that significant liver eQTL variants are more often localized within 
known gene structures and are likely regulatory variants as they are found within regions of transcription factor 
binding and open chromatin. In addition, the most significant variants are also the most likely functional variant 
in each eQTL. This is supported by findings that the most significant eQTL variants (i) show an increased level 
of enrichment in all relevant RegulomeDB score categories compared to all eQTL variants and (ii) are enriched 
within known gene structures such as introns or coding exons.
Liver eQTL in AMD. Finally, we investigated whether any of the 52 independent AMD associated variants 
reported by Fritsche et al.3 coincides with the established liver eQTL. Out of 52 independent tag variants, only 31 
variants had an allele frequency >5% and could be reliably imputed into our dataset. Remarkably, 8 of these 31 
variants significantly affect 15 unique eQTL-genes (Q-Value < 0.05, Table 2).
Within the complement factor H (CFH) locus, several AMD associated variants appear to influence expres-
sion of CFH and CFH related genes (CFHR). Particularly, the independent hit variant rs10922109 (independent 
hit 1–1 in3) tags a common deletion of CFHR1/CFHR3. Since the deletion of both genes is protective against 
AMD, the risk increasing allele results in elevated expression of the two genes (Table 2).
Notably, two genes involved in HDL metabolism, Cholesteryl ester transfer protein (CETP) and hepatic lipase 
(LIPC), were both significantly regulated by AMD associated variants (Table 2). Specifically, rs17231506 is highly 
correlated to rs3764261 (R² > 0.99), a variant that results in markedly increased HDL levels in blood31. According 
to our eQTL data, rs17231506 reduces the expression of CETP, in line with the observation that CETP deficiency 
or pharmacological inhibition leads to elevated serum HDL. Further, our eQTL data showed that rs2070895 
(−250 G > A) increases the expression of LIPC and would be expected to be associated with decreased HDL 
blood32.
Finally, we identified additional AMD associated variants that potentially act as eQTL in liver. The AMD 
risk increasing allele of rs7803454 increases the expression of the paired immunoglobin like type 2 receptor 
alpha (PILRA) and beta (PILRB) genes. The resulting proteins are known to function as antagonists within the 
Tyrosine-protein phosphatase non-receptor type 6 (PTPN6) pathway33 and have been implicated in both, AMD 
and Alzheimer’s disease risk34. Interestingly, we did not detect any eQTL within the strongest AMD associated 
locus located on chromosome 10q26 (ARMS2/HTRA1).
Discussion
In this study, we have combined the genotypes and expression data of four previously published independent 
studies to further our understanding of the regulatory networks in liver tissue. Each individual study intended to 
identify new liver specific eQTL in order to elucidate the contribution of regulatory mechanisms on different dis-
eases or traits. For example, Schadt et al.18 were the first to explore eQTL in liver tissue and correlated their results 
to genome-wide association studies of seven different diseases. AMD was not among them. Innocenti et al.17 and 
Schroeder et al.19 followed a similar approach but concentrated on the reproducibility of eQTL, while the latter 
group additionally focused on genes involved in drug response pathways. GTEx analysed eQTL in 44 human 
tissues and aimed to explore the interplay of gene regulation across tissues. By merging these resources this is 
to our knowledge the largest study on liver eQTL to date and promises to provide novel insight into the role of 
genetic variation on gene expression in liver tissue. Combining several studies while jointly analysing the data has 
drastically increased the power to detect novel eQTL across the genome. The replication rates of eQTL detected 
in individual studies can be as low as 38.5% (Table 1), even with a stringent FDR threshold of 0.1%. An approach 
Figure 2. Characterisation of independent signal eQTL variants based on their genomic localisation. The 
distance to the nearest transcription start site (TSS) is plotted against the −log10 P-Values of the most significant 
variant at each eQTL gene, including secondary signals (independent hits). Negative/positive distances denote 
that the variant is located upstream/downstream of the TSS with regard to the direction of transcription.
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known as mega-analysis has further improved the power of our study to detect novel eQTL. This also revealed 
a higher replication rate of eQTL identified by individual studies. Although the gain in power attributable to a 
mega-analysis can depend on the type of study23, the mega-analysis approach allowed us to identify additional, 
independent signals in 5% of the significant eQTL.
Mapping identified eQTL-variants against known gene structures such as introns, coding or non-coding 
exons revealed that a large proportion of the identified eQTL variants is highly enriched in intronic and cod-
ing regions of genes, in line with previous results13,16, although such an enrichment may be specific for certain 
tissues35. Similarly, we have observed a strong enrichment of eQTL variants in RegulomeDB classes one to four 
representing known eQTL and expected regulatory variants. Since many eQTL are shared between tissues20, an 
enrichment in RegulomeDB class 1 (representing known eQTL) is not surprising. Nevertheless, we also observe a 
strong enrichment of eQTL variants in RegulomeDB classes two to four, representing variants in experimentally 
determined regulatory epigenetic elements. Importantly, hypothetic regulatory variants in RegulomeDB class 
Figure 3. Functional annotations and predicted consequences of local eQTL-variants. Three sets of variants 
were evaluated by employing two different databases. Set one (control) includes random variants of the imputed 
genotype file, which are located next to at least one gene within a distance of a maximum of 1 Mb. Set two 
(mega-analysis) consists of all significant mega-analysis (Q-Value < 1 × 10−3) eQTL variants while the third 
group comprises the most significant variant of each independent hit (including the independent secondary 
signal variants). (A) The chart depicts the percentage of variants per variant set categorised into seven groups 
by RegulomeDB. The seven-level functional score is based on a synthesis of data derived from various sources: 
category 1 variants are very likely to affect binding and are linked to gene expression of a target gene (i.e. are 
known eQTL variants); categories 2 and 3 are likely to affect at least transcription factor binding and several 
other regulatory effects; categories 4–6 show minimal functional indication while category 7 variants lack 
evidence for any functional relevance. (B) The chart shows the percentage of variants classified into ten classes 
of consequences according to the Ensembl Variant Effect Predictor (VEP). For variant set two (mega-analysis) 
and three (independent hits) we only included the predicted consequence affecting the identified eQTL gene. 
For the control group, one random gene within a variant–gene distance of a maximum of 1 Mb was chosen. We 
selected the most severe effect, if the variant had different effects on transcripts of the same gene. ***P-Value for 
difference between groups <0.001.
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5 (characterized by either transcription factor binding or a peak of DNase hypersensitivity) are not enriched in 
the identified liver eQTL variants, greatly increasing confidence in the robustness of our results. Alternatively, 
variants in RegulomeDB class 5 could be variants with weaker regulatory effects and thus, our study might be 
underpowered to identify significant eQTL variants that are characterized by mapping to a weak epigenetic mark.
Strikingly, the observed enrichment in gene structures were more pronounced in the independent hits which 
represented the most significantly associated variants and, in addition, the most significantly associated second-
ary signals. This strengthen the notion that the variant showing the smallest P-value of association or correlation 
in a locus is a priori the most likely one to be the true causative mutation36. Alternatively, it is also possible that 
the functional allele of the variant with the smallest P-value is rather tagging several haplotypes that affect gene 
expression in the same orientation37. Therefore, in case a defined eQTL is of major interest, such a locus has to be 
dissected further by statistical means to identify all independent haplotypes carrying functional alleles10.
While the central nervous system and the retina are expressing complement genes, the liver is nevertheless 
the primary site of synthesis for circulatory complement proteins38. In addition, the liver plays a key role in lipid 
metabolism39, besides the complement cascade another pathway implicated in AMD pathology by epidemiolog-
ical and genetic studies. We therefore investigated whether any of the top hits of a recent GWAS for AMD3 are 
regulatory variants influencing gene expression in liver.
One of the most significant association signals for AMD resides within the CFH locus on chromosome 1 and 
represents a compound signal of two protective haplotypes tagged by the protective allele of the top variant37. One 
protective haplotype harbors a common deletion of the CFH-related genes 1 and 3 (CFHR1/3)40. The heterozy-
gous deletion of both genes results in reduced levels of CFHR1/3 proteins in serum, while a homozygous deletion 
results in a complete absence of CFHR1/341,42. In line with this, we found that the AMD risk increasing allele of 
rs6677604 is correlated to increased expression of both genes while the protective allele of rs6677604 (in strong 
linkage disequilibrium with the CFHR1/3 deletion) is correlated with decreased expression. In addition, the pro-
tective allele reduces the expression of other CFHR genes as well as the expression of the CFH gene. Since CFH 
and CFH-related genes share high sequence identity with each other, the expression values of the individual gene 
may not be distinguishable from the related gene by currently used high-throughput methods43–45. Indeed, we 
found that the gene expression values of CFH and CFH-related genes (CFHR1-5) are correlated in liver samples 
(R² between 0.1 and 0.5).
One important result of our study reveals that two AMD-associated signals near LIPC and CETP are signif-
icant eQTL, strongly implicating HDL metabolism and serum lipid levels in AMD pathogenesis. We observed 
that the AMD risk increasing allele of rs17231506 reduces CETP expression, likely resulting in elevated HDL 
levels in serum46. This is in line with the observation that HDL levels are elevated in AMD patients compared 
to controls7–9. Further, the risk increasing allele of rs2070895 near LIPC results in increased expression of LIPC, 
which is generally associated with reduced serum HDL levels47. A study by Burgess and Smith48 also observed an 
AMD associated variant next to LIPC (rs261342) to be associated with decreased HDL serum levels48. This vari-
ant is in high linkage disequilibrium with rs2070895 (R2 = 0.84) which was shown in our study to cause elevated 
LIPC expression in liver. Burgess and Smith48 in addition demonstrated that the AMD risk associated variant 
rs261342 predominately results in reduced LDL and increased HDL levels. Of note, CETP and LIPC genes are 
IH* dbSNP ID CHR
Position 













1.2 rs570618 chr1 196,657,064 ENSG00000244414 CFHR1 2.15E-12 4.34E-10 0.711 0.099 G T 0.360307 −131822
1.1 rs10922109 chr1 196,704,632 ENSG00000134365 CFHR4 3.29E-24 1.66E-21 1.118 0.105 A C 0.554124 −114738
1.1 rs10922109 chr1 196,704,632 ENSG00000244414 CFHR1 7.56E-24 2.54E-21 0.992 0.094 A C 0.554124 −84254
1.1 rs10922109 chr1 196,704,632 ENSG00000116785 CFHR3 8.38E-17 2.11E-14 0.923 0.107 A C 0.554124 −39292
1.1 rs10922109 chr1 196,704,632 ENSG00000143278 F13B 0.0002 0.012 0.216 0.057 A C 0.554124 −303688
1.1 rs10922109 chr1 196,704,632 ENSG00000000971 CFH 0.0004 0.025 0.338 0.095 A C 0.554124 83625
1.6 rs61818925 chr1 196,815,450 ENSG00000116785 CFHR3 1.38E-08 1.55E-06 0.649 0.113 G T 0.417647 71526
1.6 rs61818925 chr1 196,815,450 ENSG00000244414 CFHR1 5.97E-05 0.006 0.416 0.103 G T 0.417647 26564
1.6 rs61818925 chr1 196,815,450 ENSG00000134389 CFHR5 0.0001 0.011 −0.371 0.096 G T 0.417647 −131216
11 rs7803454 chr7 99,991,548 ENSG00000121716 PILRB 5.67E-27 5.72E-24 0.251 0.022 C T 0.188567 57812
11 rs7803454 chr7 99,991,548 ENSG00000085514 PILRA 6.16E-11 1.04E-08 0.372 0.056 C T 0.188567 26396
23.1 rs2043085 chr15 58,680,954 ENSG00000128918 ALDH1A2 0.0002 0.016 0.207 0.056 T C 0.667257 435333
23.2 rs2070895 chr15 58,723,939 ENSG00000166035 LIPC 5.45E-09 6.88E-07 0.561 0.095 A G 0.80531 21172
23.2 rs2070895 chr15 58,723,939 ENSG00000137845 ADAM10 0.0003 0.021 −0.217 0.06 A G 0.80531 −163463
24.2 rs17231506 chr16 56,994,528 ENSG00000087237 CETP 8.48E-05 0.008 −0.216 0.055 C T 0.327434 −1233
27 rs6565597 chr17 79,526,821 ENSG00000182612 TSPAN10 1.70E-09 2.46E-07 −0.526 0.086 C T 0.383459 −77375
27 rs6565597 chr17 79,526,821 ENSG00000184009 ACTG1 0.0002 0.016 0.312 0.084 C T 0.383459 49825
27 rs6565597 chr17 79,526,821 ENSG00000141552 ANAPC11 0.0006 0.036 −0.171 0.05 C T 0.383459 −321844
Table 2. eQTL variants overlapping with genome-wide significant AMD variants. CHR: chromosome; TSS: 
transcription start site; SE: standard error of the effect size. *IH: independent hit according to Fritsche et al.3. 
**Effect size (beta) of a single AMD risk increasing allele.
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key regulators of HDL remodelling which might be essential for efficient delivery of lipids (e.g. fatty acids, carote-
noids) into the retina and efflux of excess lipids out of the retina. Importantly, CETP and LIPC variants have been 
shown to have additive effects on cardiovascular risk with low CETP activity variants combined with low LIPC 
activity variants increased the risk49. Cardiovascular risk could therefore add additional pressure to select specific 
variant gene combinations in the aged AMD population that were protected from cardiovascular death. A simi-
lar line of thought emerged from another recent study, which found that a genetic score based on genome-wide 
significant variants for elevated HDL serum levels was higher in AMD patients, strongly suggesting that AMD 
patients have more alleles that increase HDL than controls50, in line with other studies51,52. Other confounding 
variables such as exercise, drugs or alcohol consumption or the occurrence of AMD in study participants are 
potentially influencing our eQTL analysis. However, the individuals in the study were largely below 60 years of 
age (404 out of 588) and thus AMD associated impairment such as an overly sedentary life style should play a 
minor role in confounding our analysis. Furthermore, this study included a diverse and large set of individuals 
across multiple studies, which should reduce the effect of confounding environmental factors, especially since 
AMD associated factors are not likely to significantly influence confounders such as alcohol consumption53,54 or 
treatment with different, liver-metabolized drugs.
Conclusions
We present the currently most comprehensive eQTL analysis for liver tissue and report that 1,959 out of 24,123 
investigated genes have at least one significant eQTL in liver. Significant eQTL variants are more frequently found 
within gene boundaries and are more enriched in RegulomeDB classes representing likely regulatory variants. 
Several of these liver eQTL overlap with genetic variants strongly associated with AMD at genome-wide signifi-
cance. These findings underscore the validity of the eQTL approach to identify disease-associated functional vari-
ants and provide further confirmation that HDL metabolism is strongly involved in AMD aetiology. Nevertheless, 
it should be emphasized that further replication of our results in disease relevant tissues such as retina or RPE or 
other functional validation studies are warranted. Specifically, this could further validate our notion that HDL 
metabolism is, in addition to the complement cascade, a major pathway in AMD disease development.
Methods
Genotype data. The genotypes of the four studies were retrieved from the respective databases (Table 1). 
Genotype quality control was performed for each study separately and, in addition, jointly after imputation. Since 
some studies reported only the zygosity of their samples at each variant (e.g. homozygosity: AA or BB; heterozy-
gosity: AB), we first matched the reported alleles of each variant to the respective allele in the 1000 Genomes 
reference dataset to the Biomart30,55 online database (http://grch37.ensembl.org/biomart/). Multi-allelic variants 
were excluded to avoid potential ambiguity. Next, for each study we extracted the genotypes of all samples at 
30,000 randomly chosen variants from all autosomes. We also included the genotypes of all samples from the 
1000 Genomes Project Phase 3 (release 20130502)56 at the same variants and performed a PCA with the snpgd-
sPCA function of the SNPRelate57 package in R58. Since the haplotype structure can greatly vary between popu-
lations, we only included individuals clustering next to the European (EUR) reference individuals in the eQTL 
analyses (Supplementary Fig. S1). We then compared the reference allele in the datasets to the reference allele 
in the European 1000 Genomes samples. Alleles were flipped when given on the opposite strand. We excluded 
variants whose reference allele frequency differed by more than 10% from the reference allele frequency of the 
1000 Genomes European samples. Furthermore, we excluded variants that were (1) not on autosomes, (2) had 
a minor allele frequency of MAF < 0.05 or deviated significantly from Hardy-Weinberg equilibrium59 (HWE, 
P < 1 × 10−6) after applying the respective function in the VCFtools60.
The individual genotype data sets were merged into a single VCF file. Variants which were not present in 
an individual study or were not genotyped in at least 100 samples were assigned missing in the respective indi-
viduals. Phasing and imputation was performed on the merged data, as accuracy of both algorithms increases 
with increasing sample sizes61. Phasing was performed with SHAPEIT2 and standard settings by supplying the 
imputed genotypes from the 1000 Genomes Phase 3 reference panel62. The same reference panel was used to 
conduct a whole genome imputation with IMPUTE263 at standard settings. Next, VCFtools was used to remove 
variants with a minor allele frequency < 5% and variants which showed evidence for a significant deviation from 
Hardy-Weinberg equilibrium (P < 1 × 10−6). In addition, variants with an IMPUTE2 info score smaller than 0.4 
considered to be of low quality64, were removed. Finally, the reference allele frequency of each study was com-
pared against the reference allele frequency of all other studies (Supplementary Fig. S2). Variants whose reference 
allele frequency differed by more than 15% between studies were excluded.
Specifics for each data set were as follows:
The GTEx data were retrieved through dbGAP65 (https://www.ncbi.nlm.nih.gov/gap, accession: phs000424.
v6.p1). The positions of the variants were already reported based on the final hg19 build and thus, no additional 
lift-over was required.
Innocenti et al.17 genotype information was retrieved from the GEO database66 (accession code: GSE26105). 
The genotyping had been performed by the authors on an Illumina 610 Quad chip and the genotypes were 
encoded by each individual’s zygosity status (homozygosity: AA, BB; or heterozygosity: AB). The hg19 coordi-
nates as well as the respective alleles of the variants were retrieved from Ensemble by querying the Biomart online 
database with the respective dbSNP identifier.
The genotype information from Schroeder et al.19 was retrieved from the GEO database (accession: GSE39036). 
The samples had been genotyped by the authors on an Illumina HumanHap300 chip and the genotypes were 
also encoded according to the individual zygosity status. The hg19 coordinates and alleles were retrieved from 
Ensemble as specified above.
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The genotypes from the Schadt et al.18 study were retrieved from the Synapse database (accession: syn89614). 
The samples had been genotyped on either the Affymetrix 500k or the Illumina 650 Y genotyping chip. The gen-
otype file included hg17 positions of each variant, a unique dbSNP identifier and both alleles of each individual. 
We initially removed variants without dbSNP identifiers and then used the program liftover67 from the UCSC 
Genome Browser (https://genome.ucsc.edu/util.html) to retrieve the hg19 coordinates of each variant.
Gene expression data. The present study included the gene expression data from four independent stud-
ies. Three studies profiled gene expression by employing microarray platforms (Table 1) while one study used 
high-throughput transcriptome sequencing (RNA-Seq) for data generation. First, we remapped array probes to 
an in silico mRNA reference database based on Ensemble gene annotation30 with the help of the ReAnnotator 
pipeline68. Only exome-matching probes showing less than five mismatches were retained in the data set. Probes 
mapping to multiple genes or overlapping with common variants (according to dbSNP release 142) were removed 
from the analysis69. Probes which measured the gene expression of the same gene, were merged by calculating 
the mean of all probes within a gene, weighted by the variance of the respective probe over all samples. Hence, 
probes with a higher variance contributed more to the overall transcript levels than probes with little variation 
across samples.
For each data set, we performed basic expression normalization and quality control. Briefly, the available 
expression values were log2-transformed and a PCA was performed with the prcomp function in R to detect 
potential outlier samples within the dataset. We merged replicate samples by taking the mean of all replicate 
values.
The expression data of the four studies were merged and missing expression values were imputed using the 
K-Nearest-Neighbour70 method provided by the impute.knn function of the impute Bioconductor package71 in R. 
Genes that were included in one study but could not be imputed into the other studies were removed. Differences 
between all individuals were evaluated by conducting a PCA on the gene expression data (Supplementary 
Fig. S3A–C). In addition, the expression values for each individual were plotted as a boxplot (Supplementary 
Fig. S3D–F). Due to substantial differences between datasets, we applied further normalisation steps. Initially, we 
performed a quantile normalisation with the normalize.quantiles function of the R package preprocessCore72,73. 
Since quantile normalization alone was not sufficient to normalize all studies, we adopted an empirical batch 
correction method called ComBat with the combat function from the sva package in R74. By supplying known 
batch effects to the function (i.e. the study labels), ComBat standardises the data gene-wise and then applies an 
empirical batch effect correction (Supplementary Fig. S3C and F). The batch corrected expression values were 
used for the eQTL analyses, as no obvious bias of the single studies was noticeable.
Methods specific to the individual studies were as follows:
Firstly, for the GTEx data expression values (release GTex-V6p) were downloaded from the GTEx Portal 
(http://www.gtexportal.org/home/). The levels of transcript expression were encoded as “reads per kilobase of 
transcript per million mapped reads” (RPKM). We added 0.001 to all RPKM values to perform a log2 transfor-
mation of the data.
Secondly, the expression data from Innocenti et al.17 were retrieved from the gene expression omnibus (GEO) 
database (https://www.ncbi.nlm.nih.gov/geo/, accession: GSE25935). The expression values were already back-
ground subtracted and transformed to the log2 scale.
Thirdly, Schadt et al. (2008) provided a curated version of their data in the Synapse database (https://www.
synapse.org/, accession: syn89614). As this study used an Agilent Custom 44k array, probe sequences were not 
openly available. In addition, not all samples had values for both genotype and gene expression data. The authors 
supplied an annotation file which links probe IDs to Ensemble and RefSeq75 identifiers. Expression values of 
probes were only used, if they were unanimously linked to a single Ensemble or RefSeq identifier. Furthermore, 
RefSeq identifiers were converted to Ensemble gene identifiers with the help of the Ensembl biomart tool55. A 
Shapiro–Wilk test76 revealed that raw values larger than 2 or smaller than −2 values are likely outliers. Thus, all 
of these were set to missing.
Finally, expression values from Schroeder et al.19 were retrieved from the GEO database (accession: GSE32504) 
as quantile normalized data. To retrieve probe sequences of the Illumina Human WG-6v2.0 chip for probe remap-
ping, the illuminaHumanv2.db R package77 was used.
eQTL analysis. Linear regression analysis between gene expression values and imputed allele dosages was 
performed with Matrix eQTL78. Age, gender and the first five principal components of the genotype PCA were 
included in the models as covariates. We exclusively calculated local eQTL (variant-gene distance less than one 
million base pairs) due to limited power to perform distant eQTL analyses15.
Two approaches were adopted to jointly analyse eQTL. First, a classic meta-analysis was applied to the indi-
vidual study results. The effect size (slope) and standard error of the effect size were estimated with Matrix eQTL 
for each study separately. Further, a random effects model implemented in the function MiMa79 was applied to 
estimate the joint effect sizes and standard errors as well as the joint P-Values. The latter approach (mega-analysis) 
estimated local eQTL from the merged genotype and expression data directly. This approach also allowed us to 
search for novel independent eQTL for a gene by adjusting the linear regression model for the most significant 
eQTL variant for this gene. To account for multiple testing, the false discovery rate (FDR) was controlled to be 
smaller than 0.001. Thus, joint Q-Values were considered to be smaller than 0.001 for statistical significance.
Functional annotation of eQTL variants. A control set of variants was generated by randomly choosing 
around 200,000 genetic variants within 1 Mbp of a gene locus (defined by the transcription start and stop site of 
each gene). A RegulomeDB score (www.regulomedb.org/) was then assigned to each control and eQTL variant. 
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The score denotes the confidence that a certain variant is important for transcription factor binding or chromatin 
accessibility and thus gene regulation. Variants in classes one to four are deemed very likely regulatory variants, 
while variants in classes five to seven are less likely to influence gene expression. In addition, the Ensembl Variant 
Effect Predictor (VEP, www.ensembl.org/vep) was used to assign each eQTL variant to a functional consequence 
relative to known gene structures. The program predicted the most severe consequence per gene within a range 
of 1 Mbp up and downstream of each variant. For eQTL variants, only predicted consequences affecting the 
associated eQTL gene were evaluated. For the control variants, a single random consequence for a nearby gene 
was chosen.
Ethics approval and consent to participate. This study used data of four public datasets. For further 
specifics on the respective ethics approvals, we refer to the single study publications.
Data availability statement. All data are available in public databases as detailed in the methods section.
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